Literature DB >> 28612035

Method for detecting voxelwise changes in fluorodeoxyglucose-positron emission tomography brain images via background adjustment in cancer clinical trials.

Lei Qin1, Armin Schwartzman2, Keisha McCall1, Nezamoddin N Kachouie3, Jeffrey T Yap4.   

Abstract

An important challenge to using fluorodeoxyglucose-positron emission tomography (FDG-PET) in clinical trials of brain tumor patients is to identify malignant regions whose metabolic activity shows significant changes between pretreatment and a posttreatment scans in the presence of high normal brain background metabolism. This paper describes a semiautomated processing and analysis pipeline that is able to detect such changes objectively with a given false detection rate. Image registration and voxelwise comparison of the pre- and posttreatment images were performed. A key step is adjustment of the observed difference by the estimated background change at each voxel, thereby overcoming the confounding effect of spatially heterogeneous metabolic activity in the brain. Components of the proposed method were validated via phantom experiments and computer simulations. It achieves a false response volume accuracy of 0.4% at a significance threshold of 3 standard deviations. It is shown that the proposed methodology can detect lesion response with 100% accuracy with a tumor-to-background-ratio as low as 1.5, and it is not affected by the background brain glucose metabolism change. We also applied the method to FDG-PET patient images from a clinical trial to assess treatment effects of lapatinib, which demonstrated significant changes in metabolism corresponding to tumor regions.

Entities:  

Keywords:  brain oncology; image analysis; neuroimaging; positron emission tomography

Year:  2017        PMID: 28612035      PMCID: PMC5452430          DOI: 10.1117/1.JMI.4.2.024006

Source DB:  PubMed          Journal:  J Med Imaging (Bellingham)        ISSN: 2329-4302


  22 in total

1.  On the origin of cancer cells.

Authors:  O WARBURG
Journal:  Science       Date:  1956-02-24       Impact factor: 47.728

2.  A unified statistical approach for determining significant signals in images of cerebral activation.

Authors:  K J Worsley; S Marrett; P Neelin; A C Vandal; K J Friston; A C Evans
Journal:  Hum Brain Mapp       Date:  1996       Impact factor: 5.038

Review 3.  Pseudoprogression and pseudoresponse: imaging challenges in the assessment of posttreatment glioma.

Authors:  L C Hygino da Cruz; I Rodriguez; R C Domingues; E L Gasparetto; A G Sorensen
Journal:  AJNR Am J Neuroradiol       Date:  2011-03-10       Impact factor: 3.825

4.  Summary of the UPICT Protocol for 18F-FDG PET/CT Imaging in Oncology Clinical Trials.

Authors:  Michael M Graham; Richard L Wahl; John M Hoffman; Jeffrey T Yap; John J Sunderland; Ronald Boellaard; Eric S Perlman; Paul E Kinahan; Paul E Christian; Otto S Hoekstra; Gary S Dorfman
Journal:  J Nucl Med       Date:  2015-04-16       Impact factor: 10.057

5.  The [18F]fluorodeoxyglucose method for the measurement of local cerebral glucose utilization in man.

Authors:  M Reivich; D Kuhl; A Wolf; J Greenberg; M Phelps; T Ido; V Casella; J Fowler; E Hoffman; A Alavi; P Som; L Sokoloff
Journal:  Circ Res       Date:  1979-01       Impact factor: 17.367

6.  Measurement of clinical and subclinical tumour response using [18F]-fluorodeoxyglucose and positron emission tomography: review and 1999 EORTC recommendations. European Organization for Research and Treatment of Cancer (EORTC) PET Study Group.

Authors:  H Young; R Baum; U Cremerius; K Herholz; O Hoekstra; A A Lammertsma; J Pruim; P Price
Journal:  Eur J Cancer       Date:  1999-12       Impact factor: 9.162

7.  FDG-PET changes in brain glucose metabolism from normal cognition to pathologically verified Alzheimer's disease.

Authors:  Lisa Mosconi; Rachel Mistur; Remigiusz Switalski; Wai Hon Tsui; Lidia Glodzik; Yi Li; Elizabeth Pirraglia; Susan De Santi; Barry Reisberg; Thomas Wisniewski; Mony J de Leon
Journal:  Eur J Nucl Med Mol Imaging       Date:  2009-01-14       Impact factor: 9.236

Review 8.  From RECIST to PERCIST: Evolving Considerations for PET response criteria in solid tumors.

Authors:  Richard L Wahl; Heather Jacene; Yvette Kasamon; Martin A Lodge
Journal:  J Nucl Med       Date:  2009-05       Impact factor: 10.057

9.  Phase II trial of lapatinib for brain metastases in patients with human epidermal growth factor receptor 2-positive breast cancer.

Authors:  Nancy U Lin; Lisa A Carey; Minetta C Liu; Jerry Younger; Steven E Come; Matthew Ewend; Gordon J Harris; Elizabeth Bullitt; Annick D Van den Abbeele; John W Henson; Xiaochun Li; Rebecca Gelman; Harold J Burstein; Elizabeth Kasparian; David G Kirsch; Ann Crawford; Fred Hochberg; Eric P Winer
Journal:  J Clin Oncol       Date:  2008-04-20       Impact factor: 44.544

Review 10.  SPM: a history.

Authors:  John Ashburner
Journal:  Neuroimage       Date:  2011-10-17       Impact factor: 6.556

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.